Moreover, specific oncometabolites, such as 2-hydroxyglutarate (2-HG), in isocitrate dehydrogenase (IDH)-mutant cancers act as epigenetic modifiers and reinforce cancer-promoting programs (43, 46). Here, IDH1 is linked to cancer.